Rosewind CORP just filed a prospectus, suggesting it plans to soon issue some securities

Rosewind CORP just came out with a new prospectus, available here. This is an SEC requirement for firms looking to issue certain types of securities. An excerpt of the prospectus is provided below:

424B3 1 v464156_424b3.htm 424B3   Prospectus Supplement filed pursuant to Rule 424(b)(3) in connection with Registration Statement No. 333-213489     Aytu BioScience, Inc.   Prospectus Supplement No. 1 dated April 12, 2017 (to Prospectus dated April 4, 2017)   1,076,596 shares of common stock     This Prospectus Supplement No. 1 updates, amends, and supplements the information previously included in our prospectus dated April 4, 2017, which we refer to as our prospectus, relating to the offer for sale or other disposition of an aggregate of 1,076,596 shares of common stock, $0.0001 par value per share, of Aytu BioScience, Inc., issued and issuable to Lincoln Park Capital Fund, LLC, the selling shareholder named in the prospectus.   Disposition of Primsol Asset   On March 31, 2017, we entered into and closed on an Asset Purchase Agreement with Allegis Holdings, LLC (the “Purchaser”). Pursuant to the agreement, we sold to the Purchaser all of our assets related to our product known as Primsol® (trimethoprim solution), including certain intellectual property and contracts, inventory, work in process and all marketing assets and materials related solely to Primsol (together, the “Primsol Asset”). We retain any liability associated with the Primsol Asset that occurred prior to the closing. The Purchaser paid us $1,750,000 at the closing for the Primsol Asset.   The agreement contains customary representations and warranties and covenants by each party. The agreement contains customary indemnification provisions by each party, including, subject to certain limitations, the indemnification by each party for any losses arising out of any breach of the other party’s representations or warranties or any breach or failure to perform any of its covenants under the agreement, as well as any liabilities related to the Primsol Asset prior to the closing (as to the Purchaser) and after the closing (as to us).   The agreement also provides that for a period of 24 months after th

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Rosewind CORP makes a similar move, sign up!

Other recent filings from the company include the following:

General form for registration of securities under the Securities Act of 1933 - Sept. 22, 2017
General form for registration of securities under the Securities Act of 1933 - Sept. 5, 2017
Rosewind: Aytu Bioscience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update - Aug. 31, 2017
Rosewind CORP Just Filed Its Annual Report: Note 14 – Subsequ... - Aug. 31, 2017
Rosewind: Aytu Bioscience Provides Fiscal Fourth Quarter And Year-End 2017 Business Update - Aug. 31, 2017

Auto Refresh

Feedback